Expert: Monoclonal antibody targeting tissue factor pathway inhibitor (TFPI). By neutralizing TFPI, it removes the negative regulation of the extrinsic pathway, enabling increased thrombin generation through the TF/FVIIa/FXa pathway, bypassing the need for FVIIIa in the intrinsic pathway.

Everyday: Removes a natural brake on clotting. Normally, TFPI slows down clotting — which is fine if your clotting system works. But in hemophilia, the clotting system is already weak, so removing this brake helps compensate. Like taking the parking brake off a car that already has a weak engine.

Targets: []

Anti-TFPI antibody from Pfizer. Approved Oct 2024 for Hem A/B WITHOUT inhibitors. Expanding to inhibitor population (Phase 3 BASIS trial: 93% reduction in treated bleeds). Same MOA class as Alhemo (anti-TFPI) but weekly dosing vs daily. Both Hem A and Hem B.

{"notes":"No thromboembolic events in pivotal trial, but monitored given class effect.","key_risks":["Injection site reactions","Headache","Potential thromboembolic risk (class effect for anti-TFPI)"]}